Home METALS Hot Movers: CBOE Holdings, Inc (NASDAQ:CBOE), Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Hot Movers: CBOE Holdings, Inc (NASDAQ:CBOE), Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

0
0

CBOE Holdings, Inc (NASDAQ:CBOE) shares dropped 4.13% and closed at $48.74. The company on August 2 reported second quarter 2013 net income allocated to common stockholders of $45.5 million, or $0.52 per diluted share, compared with $37.9 million, or $0.44 per diluted share in the second quarter of 2012.  Adjusted net income allocated to common stockholders was $47.0 million, or $0.54 per share, compared with $37.9 million, or $0.44 per diluted share, in the same period last year.  Operating revenues of $150.8 million for the second quarter increased 14 percent compared with $132.6 million in the second quarter of 2012.

Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) shares decreased 3.70% to $3.38. The company will release its 2Q13 Earnings on August 12, 2013 (after trading hours).

Additionally, the company on July 18 announces that flights between Sao Paulo/Guarulhos and New York and Detroit operated by Delta Air Lines are now available for purchase on the sales channels of GOL. Customers can now purchase Delta flights on those routes at GOL’s website (www.voegol.com), Voe GOL stores, GOL’s call center and travel agents.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares dropped 3.61% to $4. RIGL) will release its Q213 earnings data on Tuesday, August 6th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.30) per share for the quarter.

Additionally, RIGL and AstraZeneca AB (AZ) on June 4 announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).